ICON Public (NASDAQ:ICLR) Given New $275.00 Price Target at Barclays

ICON Public (NASDAQ:ICLR) had its price objective reduced by Barclays from $330.00 to $275.00 in a research note published on Friday, Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A number of other research firms also recently issued reports on ICLR. The Goldman Sachs Group decreased their price objective on ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a report on Friday. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Leerink Partners cut their price objective on shares of ICON Public from $376.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday. Robert W. Baird lowered shares of ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 price target on the stock. in a research note on Thursday. Finally, Truist Financial reduced their price objective on shares of ICON Public from $383.00 to $363.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $310.45.

ICON Public Stock Down 0.6 %

ICLR stock traded down $1.26 during mid-day trading on Friday, hitting $220.47. 2,593,338 shares of the company were exchanged, compared to its average volume of 638,548. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31. ICON Public has a 1-year low of $220.01 and a 1-year high of $347.72. The firm’s 50 day simple moving average is $297.75 and its 200 day simple moving average is $310.26. The firm has a market cap of $18.19 billion, a P/E ratio of 25.70, a P/E/G ratio of 1.35 and a beta of 1.22.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The company had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The company’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.10 earnings per share. On average, sell-side analysts predict that ICON Public will post 14.53 EPS for the current fiscal year.

Institutional Trading of ICON Public

A number of hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC raised its stake in ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 42 shares during the period. Motco raised its position in shares of ICON Public by 1.5% in the first quarter. Motco now owns 3,882 shares of the medical research company’s stock valued at $1,304,000 after purchasing an additional 59 shares during the period. First National Bank of Hutchinson raised its position in shares of ICON Public by 5.7% in the first quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock valued at $381,000 after purchasing an additional 61 shares during the period. Arkadios Wealth Advisors boosted its holdings in shares of ICON Public by 5.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after buying an additional 62 shares during the period. Finally, GAMMA Investing LLC grew its stake in ICON Public by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after buying an additional 87 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.